Tumor mutational burden is not predictive of cytotoxic chemotherapy response.
Tumor mutational burden
biomarker
cytotoxic chemotherapy
oncology
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
24 06 2020
24 06 2020
Historique:
entrez:
14
9
2020
pubmed:
15
9
2020
medline:
15
9
2020
Statut:
epublish
Résumé
High tumor mutational burden (TMB) predicts checkpoint blockade responsiveness, although the association with outcomes may be nuanced in certain tissue contexts. The correlation between TMB and cytotoxic chemotherapy sensitivity is unknown. This study evaluated the relationship between TMB and outcome in patients with solid tumors receiving cytotoxic chemotherapy. University of California San Diego patients who received cytotoxic chemotherapy within one year after biopsy for TMB evaluation were included in a retrospective analysis. Physician notes and imaging reports in the electronic medical record were reviewed to determine clinical benefit and progression-free survival (PFS). Among 1526 patients with TMB availability, there were 294 eligible patients who received chemotherapy. There were no significant differences in TMB between those with stable disease ≥6 months/partial response/complete response versus others (t-test, In summary, TMB was not predictive of stable disease ≥6 months/partial response/complete response or PFS in patients receiving cytotoxic chemotherapy. NCT02478931.
Sections du résumé
Background
High tumor mutational burden (TMB) predicts checkpoint blockade responsiveness, although the association with outcomes may be nuanced in certain tissue contexts. The correlation between TMB and cytotoxic chemotherapy sensitivity is unknown. This study evaluated the relationship between TMB and outcome in patients with solid tumors receiving cytotoxic chemotherapy.
Methods
University of California San Diego patients who received cytotoxic chemotherapy within one year after biopsy for TMB evaluation were included in a retrospective analysis. Physician notes and imaging reports in the electronic medical record were reviewed to determine clinical benefit and progression-free survival (PFS).
Results
Among 1526 patients with TMB availability, there were 294 eligible patients who received chemotherapy. There were no significant differences in TMB between those with stable disease ≥6 months/partial response/complete response versus others (t-test,
Conclusions
In summary, TMB was not predictive of stable disease ≥6 months/partial response/complete response or PFS in patients receiving cytotoxic chemotherapy.
Trials Registration
NCT02478931.
Identifiants
pubmed: 32923144
doi: 10.1080/2162402X.2020.1781997
pii: 1781997
pmc: PMC7458654
doi:
Substances chimiques
Biomarkers, Tumor
0
Banques de données
ClinicalTrials.gov
['NCT02478931']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Pagination
1781997Subventions
Organisme : NCI NIH HHS
ID : P30 CA023100
Pays : United States
Organisme : NCATS NIH HHS
ID : TL1 TR001443
Pays : United States
Informations de copyright
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
Références
Int J Cancer. 2008 Nov 15;123(10):2384-9
pubmed: 18729195
Cancer Cell. 2007 Jan;11(1):25-36
pubmed: 17189716
Cancer Metastasis Rev. 2017 Mar;36(1):179-190
pubmed: 27873079
J Immunother Cancer. 2019 Jul 15;7(1):183
pubmed: 31307554
Cancer Immunol Res. 2016 Nov;4(11):959-967
pubmed: 27671167
Nat Rev Mol Cell Biol. 2009 Jul;10(7):478-87
pubmed: 19546858
Eur J Cancer. 2011 Jun;47(9):1319-27
pubmed: 21450455
Cancer Res. 2010 Nov 15;70(22):9253-64
pubmed: 21045157
Cancer Immunol Res. 2019 Oct;7(10):1570-1573
pubmed: 31405947
Oncoimmunology. 2018 May 24;7(8):e1466768
pubmed: 30221068
Mol Cancer Ther. 2017 Nov;16(11):2598-2608
pubmed: 28835386
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
Nat Biotechnol. 2013 Nov;31(11):1023-31
pubmed: 24142049
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Mol Cancer Ther. 2016 Aug;15(8):1781-91
pubmed: 27413114
Int J Cancer. 2020 Jun 1;146(11):3087-3097
pubmed: 31479512
Hum Pathol. 2011 Jul;42(7):1019-26
pubmed: 21315408
J Clin Oncol. 2008 Jun 1;26(16):2690-8
pubmed: 18509181
N Engl J Med. 2013 Mar 21;368(12):1101-10
pubmed: 23514287
J Clin Oncol. 2015 Aug 1;33(22):2450-6
pubmed: 26124486
Clin Cancer Res. 2005 Jan 1;11(1):298-305
pubmed: 15671559
Front Pharmacol. 2019 Jun 14;10:673
pubmed: 31258479
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155